Bioaffinity Technologies Stock Performance

BIAF Stock  USD 0.75  0.11  12.79%   
The firm shows a Beta (market volatility) of 4.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioAffinity Technologies will likely underperform. At this point, bioAffinity Technologies has a negative expected return of -1.5%. Please make sure to confirm BioAffinity Technologies' total risk alpha, skewness, rate of daily change, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if bioAffinity Technologies performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days bioAffinity Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Last Split Factor
1:30
Last Split Date
2025-09-19
1
Will bioAffinity Technologies Inc. Equity Warrant stock outperform Dow Jones index - Trade Analysis Report Daily Risk Controlled Trade Plans - newser.com
11/13/2025
2
Is bioAffinity Technologies Inc. stock a buy for dividend growth - 2025 Short Interest Accurate Technical Buy Alerts - newser.com
11/20/2025
3
bioAffinity Technologies to Present at Cancer Roundtable - TipRanks
12/03/2025
4
bioAffinity Technologies adjourns special shareholder meeting due to lack of quorum - Investing.com
12/19/2025
5
Insider Trading
01/23/2026
6
Market Recap Can bioAffinity Technologies Inc Equity Warrant weather a recession - Weekly Trade Analysis High Accuracy Swing Trade Signals - baoquankhu1.vn
01/29/2026
7
Acquisition by Anderson Robert A. of 11867 shares of BioAffinity Technologies at 1.58 subject to Rule 16b-3
02/04/2026
Begin Period Cash Flow2.8 M
Total Cashflows From Investing Activities-79.1 K

BioAffinity Technologies Relative Risk vs. Return Landscape

If you would invest  209.00  in bioAffinity Technologies on November 8, 2025 and sell it today you would lose (134.00) from holding bioAffinity Technologies or give up 64.11% of portfolio value over 90 days. bioAffinity Technologies is currently does not generate positive expected returns and assumes 6.2222% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than BioAffinity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days BioAffinity Technologies is expected to under-perform the market. In addition to that, the company is 8.13 times more volatile than its market benchmark. It trades about -0.24 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

BioAffinity Technologies Target Price Odds to finish over Current Price

The tendency of BioAffinity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.75 90 days 0.75 
about 98.0
Based on a normal probability distribution, the odds of BioAffinity Technologies to move above the current price in 90 days from now is about 98.0 (This bioAffinity Technologies probability density function shows the probability of BioAffinity Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 4.38 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, BioAffinity Technologies will likely underperform. Additionally BioAffinity Technologies has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   BioAffinity Technologies Price Density   
       Price  

Predictive Modules for BioAffinity Technologies

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as bioAffinity Technologies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.050.917.09
Details
Intrinsic
Valuation
LowRealHigh
0.102.058.24
Details
Naive
Forecast
LowNextHigh
0.010.516.69
Details
1 Analysts
Consensus
LowTargetHigh
5.466.006.66
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as BioAffinity Technologies. Your research has to be compared to or analyzed against BioAffinity Technologies' peers to derive any actionable benefits. When done correctly, BioAffinity Technologies' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in bioAffinity Technologies.

BioAffinity Technologies Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. BioAffinity Technologies is not an exception. The market had few large corrections towards the BioAffinity Technologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold bioAffinity Technologies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioAffinity Technologies within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.75
β
Beta against Dow Jones4.38
σ
Overall volatility
0.34
Ir
Information ratio -0.27

BioAffinity Technologies Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioAffinity Technologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for bioAffinity Technologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
BioAffinity Technologies generated a negative expected return over the last 90 days
BioAffinity Technologies has high historical volatility and very poor performance
BioAffinity Technologies has some characteristics of a very speculative penny stock
BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years
bioAffinity Technologies currently holds 1.5 M in liabilities. bioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 9.36 M. Net Loss for the year was (9.04 M) with profit before overhead, payroll, taxes, and interest of 1.89 M.
bioAffinity Technologies currently holds about 214.4 K in cash with (7.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Latest headline from MacroaxisInsider: Acquisition by Anderson Robert A. of 11867 shares of BioAffinity Technologies at 1.58 subject to Rule 16b-3

BioAffinity Technologies Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioAffinity Stock often depends not only on the future outlook of the current and potential BioAffinity Technologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioAffinity Technologies' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding404.3 K
Cash And Short Term Investments1.1 M

BioAffinity Technologies Fundamentals Growth

BioAffinity Stock prices reflect investors' perceptions of the future prospects and financial health of BioAffinity Technologies, and BioAffinity Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioAffinity Stock performance.

About BioAffinity Technologies Performance

By analyzing BioAffinity Technologies' fundamental ratios, stakeholders can gain valuable insights into BioAffinity Technologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioAffinity Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioAffinity Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 1.94  1.84 
Return On Tangible Assets(1.88)(1.97)
Return On Capital Employed(3.02)(2.87)
Return On Assets(1.25)(1.31)
Return On Equity(4.00)(3.80)

Things to note about bioAffinity Technologies performance evaluation

Checking the ongoing alerts about BioAffinity Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for bioAffinity Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BioAffinity Technologies generated a negative expected return over the last 90 days
BioAffinity Technologies has high historical volatility and very poor performance
BioAffinity Technologies has some characteristics of a very speculative penny stock
BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years
bioAffinity Technologies currently holds 1.5 M in liabilities. bioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 9.36 M. Net Loss for the year was (9.04 M) with profit before overhead, payroll, taxes, and interest of 1.89 M.
bioAffinity Technologies currently holds about 214.4 K in cash with (7.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Latest headline from MacroaxisInsider: Acquisition by Anderson Robert A. of 11867 shares of BioAffinity Technologies at 1.58 subject to Rule 16b-3
Evaluating BioAffinity Technologies' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate BioAffinity Technologies' stock performance include:
  • Analyzing BioAffinity Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioAffinity Technologies' stock is overvalued or undervalued compared to its peers.
  • Examining BioAffinity Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating BioAffinity Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioAffinity Technologies' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of BioAffinity Technologies' stock. These opinions can provide insight into BioAffinity Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating BioAffinity Technologies' stock performance is not an exact science, and many factors can impact BioAffinity Technologies' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for BioAffinity Stock analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges